L-AP5CAS# 79055-67-7 |
- BMS-708163 (Avagacestat)
Catalog No.:BCC2104
CAS No.:1146699-66-2
- DAPT (GSI-IX)
Catalog No.:BCC3618
CAS No.:208255-80-5
- YO-01027 (Dibenzazepine, DBZ)
Catalog No.:BCC2100
CAS No.:209984-56-5
- Semagacestat (LY450139)
Catalog No.:BCC3610
CAS No.:425386-60-3
- Flurizan
Catalog No.:BCC2342
CAS No.:51543-40-9
- E 2012
Catalog No.:BCC1540
CAS No.:870843-42-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 79055-67-7 | SDF | Download SDF |
PubChem ID | 1617109 | Appearance | Powder |
Formula | C5H12NO5P | M.Wt | 197.13 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in water | ||
Chemical Name | (2S)-2-azaniumyl-5-phosphonatopentanoate | ||
SMILES | C(CC(C(=O)[O-])[NH3+])CP(=O)([O-])[O-] | ||
Standard InChIKey | VOROEQBFPPIACJ-BYPYZUCNSA-L | ||
Standard InChI | InChI=1S/C5H12NO5P/c6-4(5(7)8)2-1-3-12(9,10)11/h4H,1-3,6H2,(H,7,8)(H2,9,10,11)/p-2/t4-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | NMDA antagonist. Also agonist at quisqualate-sensitized AP6 site, where it is more potent than the isomer D-AP5. Mixture DL-AP5 also available. |
L-AP5 Dilution Calculator
L-AP5 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 5.0728 mL | 25.364 mL | 50.7279 mL | 101.4559 mL | 126.8199 mL |
5 mM | 1.0146 mL | 5.0728 mL | 10.1456 mL | 20.2912 mL | 25.364 mL |
10 mM | 0.5073 mL | 2.5364 mL | 5.0728 mL | 10.1456 mL | 12.682 mL |
50 mM | 0.1015 mL | 0.5073 mL | 1.0146 mL | 2.0291 mL | 2.5364 mL |
100 mM | 0.0507 mL | 0.2536 mL | 0.5073 mL | 1.0146 mL | 1.2682 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- β-Estradiol - d3
Catalog No.:BCC5365
CAS No.:79037-37-9
- SNAP
Catalog No.:BCC6712
CAS No.:79032-48-7
- Masitinib (AB1010)
Catalog No.:BCC1260
CAS No.:790299-79-5
- Eurycomalin A
Catalog No.:BCN3654
CAS No.:790234-20-7
- 4'-O-Methylnyasol
Catalog No.:BCN7564
CAS No.:79004-25-4
- Camphene
Catalog No.:BCC9217
CAS No.:79-92-5
- Retinyl (Vitamin A) Palmitate
Catalog No.:BCC4749
CAS No.:79-81-2
- Lanosterol
Catalog No.:BCN3332
CAS No.:79-63-0
- Oxytetracycline (Terramycin)
Catalog No.:BCC4819
CAS No.:79-57-2
- Methacrylamide
Catalog No.:BCN8157
CAS No.:79-39-0
- Guan-fu base G
Catalog No.:BCN8493
CAS No.:78969-72-9
- DL-AP7
Catalog No.:BCC6551
CAS No.:78966-69-5
- D-AP5
Catalog No.:BCC6553
CAS No.:79055-68-8
- Boc-Alaninol
Catalog No.:BCC2730
CAS No.:79069-13-9
- Boc-Valinol
Catalog No.:BCC2695
CAS No.:79069-14-0
- Boc-Serinol(Bzl)
Catalog No.:BCC2706
CAS No.:79069-15-1
- (-)-Corlumine
Catalog No.:BCN6632
CAS No.:79082-64-7
- Polygalasaponin XXXI
Catalog No.:BCN2857
CAS No.:79103-90-5
- Lariciresinol acetate
Catalog No.:BCN4577
CAS No.:79114-77-5
- Hannokinol
Catalog No.:BCN6514
CAS No.:79120-40-4
- A-7 hydrochloride
Catalog No.:BCC6625
CAS No.:79127-24-5
- Diammonium glycyrrhizinate
Catalog No.:BCN7145
CAS No.:79165-06-3
- Apoptosis Activator 2
Catalog No.:BCC2099
CAS No.:79183-19-0
- 7-Hydroxyaristolochic acid A
Catalog No.:BCN2659
CAS No.:79185-75-4
Evidence that L-AP5 and D,L-AP4 can preferentially block cone signals in the rat retina.[Pubmed:17430605]
Vis Neurosci. 2007 Jan-Feb;24(1):9-15.
Several lines of evidence suggest that, as concentrations of two agonists of group III metabotropic glutamate receptors are increased, cone contributions to the b-wave are blocked before rod contributions. Application of L-AP5 (L-2-amino-5-phosphonobutyric acid) at concentrations of 50 microM and D,L-AP4 (D,L-2-amino-4-phosphonobutyric acid) at concentrations 2 microM had a greater effect in reducing the amplitude of the rat ERG b-wave at high light intensities than at low light intensities. The amplitude reduction occurs at flash intensities that saturate rod photoreceptor responses. When steady backgrounds are used to saturate rod photoreceptors, the b-wave responses show increased long-wavelength sensitivity. Responses on a rod saturating background are blocked by adding L-AP5 or AP4 at the above concentrations to the perfusate. Further evidence for metabotrophic receptors being involved comes from the observation that even when ionotropic glutamate receptors are pharmacologically blocked with MK801 and DNQX, AP4 selectively blocks cone contributions to the b-wave. Thus we suggest that the type III metabotrophic receptors on depolarizing cone bipolar cells or cone synaptic terminals are affected by concentrations of L-AP5 and D,L-AP4 that have minimal effects on rod bipolar cells or rod synaptic terminals.
Utilization of the resolved L-isomer of 2-amino-6-phosphonohexanoic acid (L-AP6) as a selective agonist for a quisqualate-sensitized site in hippocampal CA1 pyramidal neurons.[Pubmed:7953634]
Brain Res. 1994 Jun 27;649(1-2):203-7.
Brief exposure of rat hippocampal slices to quisqualic acid (QUIS) sensitizes neurons to depolarization by the alpha-amino-omega-phosphonate excitatory amino acid (EAA) analogues AP4, AP5 and AP6. These phosphonates interact with a novel QUIS-sensitized site. Whereas L-AP4 and D-AP5 cross-react with other EAA receptors, DL-AP6 has been shown to be relatively selective for the QUIS-sensitized site. This specificity of DL-AP6, in conjunction with the apparent preference of this site for L-isomers, suggested that the hitherto unavailable L-isomer of AP6 would be a potent and specific agonist. We report the resolution of the D- and L-enantiomers of AP6 by fractional crystallization of the L-lysine salt of DL-AP6. We also report the pharmacological responses of kainate/AMPA, NMDA, lateral perforant path L-AP4 receptors and the CA1 QUIS-sensitized site to D- and L-AP6, and compare these responses to the D- and L-isomers of AP3, AP4, AP5 and AP7. The D-isomers of AP4, AP5 and AP6 were 5-, 3- and 14-fold less potent for the QUIS-sensitized site than their respective L-isomers. While L-AP4 and L-AP5 cross-reacted with NMDA and L-AP4 receptors, L-AP6 was found to be highly potent and specific for the QUIS-sensitized site (IC50 = 40 microM). Its IC50 values for kainate/AMPA, NMDA and L-AP4 receptors were > 10, 3 and 0.8 mM, respectively. As with AP4 and AP5, sensitization to L-AP6 was reversed by L-alpha-aminoadipate.
Actions of D and L forms of 2-amino-5-phosphonovalerate and 2-amino-4-phosphonobutyrate in the cat spinal cord.[Pubmed:6145492]
Brain Res. 1982 Mar 11;235(2):378-86.
The separate optical enantiomers of 2-amino-5-phosphonovalerate (APV) and 2-amino-4-phosphonobutyrate (APB) have been tested for their ability to modify amino acid-induced and synaptic excitation of cat spinal neurones. D-(-)-APV was a highly potent and selective antagonist of amino acid-induced and synaptic excitation. Polysynaptic excitation was more susceptible to antagonism by D-APV than was monosynaptic excitation. It was considered likely that the depression of synaptic excitation by D-APV was due to the blockade of an excitatory amino acid transmitter acting at N-methyl-D-aspartate (NMDA) receptors. L-(+)-APV showed a relatively weak amino acid and synaptic blocking activity, which was similar in character to that of D-APV, and which may have been due to a slight residuum of the D isomer in the sample of the L form used. D-(-)-APB was a weak and relatively non-selective antagonist of amino acid-induced responses. In contrast, L-(+)-APB either had no effect or, at higher concentrations, enhanced these responses. Both isomers depressed synaptic responses in a proportion of the cells tested, the L form being the more potent isomer in producing this effect. Monosynaptic and polysynaptic excitations were both susceptible to this type of action. The depression of synaptic excitation by D-APB may have been due in some cases to the blockade of an excitatory amino acid transmitter. However, it is unlikely that the synaptic depressant action of L-APB is due to this mechanism.
The effects of a series of omega-phosphonic alpha-carboxylic amino acids on electrically evoked and excitant amino acid-induced responses in isolated spinal cord preparations.[Pubmed:7042024]
Br J Pharmacol. 1982 Jan;75(1):65-75.
1 The depressant actions on evoked electrical activity and the excitant amino acid antagonist properties of a range of omega-phosphonic alpha-carboxylic amino acids have been investigated in the isolated spinal cord preparations of the frog or immature rat. 2 When tested on dorsal root-evoked ventral root potentials, members of the homologous series from 2- amino-5-phosphonovaleric acid to 2-amino-8-phosphonooctanoic acid showed depressant actions which correlated with the ability of the substances to antagonize selectivity motoneuronal depolarizations induced by N-methyl-D-aspartate. 3 2-Amino-5-phosphonovalerate was the most potent substance of the series giving an apparent KD of 1.4 microM for the antagonism of responses to N-methyl-D-aspartate. 4 A comparison of the (+)- and (-)-forms of 2-amino-5-phosphonovalerate indicated that the N-methyl-D-aspartate antagonist activity and the neuronal depressant action of this substance were both due mainly to the (-)-isomer. 5 The (-)- and (+)-forms of 2-amino-4-phosphonobutyrate had different actions. The (-)-forms of this substance had a relatively weak and non-selective antagonist action on depolarizations induced by N-methyl-D-aspartate, quisqualate and kainate and a similarly weak depressant effect when tested on evoked electrical activity. The (+)-form was more potent than he (-)-form in depressing electrically evoked activity but did not antagonize responses to amino acid excitants. At concentrations higher than those required to depress electrically evoked activity, the (+)-form produced depolarization. This action was blocked by 2-amino-5-phosphonovalerate.